Novel heterocyclidene acetamide derivative

A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R 1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO 2 group, or the like; R 2 represents halogen...

Full description

Saved in:
Bibliographic Details
Main Authors YOSHITAKA MAEDA, HIDEHARU UCHIDA, TSUTOMU SATOH, TOMOYUKI KAMINO, YASUSHIGE AKADA, NAOTO KOSUGA, KEN-ICHI AMANO, DAIDO HOTTA
Format Patent
LanguageEnglish
Published 25.01.2007
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R 1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO 2 group, or the like; R 2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X 1 represents O, -NR 3 -, or -S(O)r-; X 2 represents a methylene group, O, -NR 3 -, or - S(O)r-; Q' represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.
Bibliography:Application Number: AU20060271297